This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: AXP COF CSCO HPQ VZ

Hess (HES) upgraded at Credit Suisse from underperform to neutral. $68 price target. Net asset value is improving.

HopFed Bancorp (HFBC) upgraded to buy at TheStreet Ratings.

Hewlett-Packard (HPQ - Get Report) upgraded at JP Morgan from underweight to neutral. $21 price target. Headline news will likely not get worse going forward.

H&R Block (HRB) downgraded at Morgan Stanley to underweight from equal-weight. $17 price target. IRS delays and stock run creates unattractive risk reward.

Huntsman (HUN) downgraded at Wells Fargo to market perform from overweight. $17-$19 price target. Valuation call.

IBM (IBM) downgraded at JP Morgan from overweight to neutral. $197 price target. Company has relatively lower growth potential.

Incyte (INCY) upgraded at Lazard from neutral to buy. $25 price target. Jakafi should see earlier adoption.

Intuitive Surgical (ISRG) upgraded at Lazard to buy, Lazard Capital Markets said. $600 price target. Stock is attractive, following a 10% pullback.

JDS Uniphase (JDSU) downgraded at Goldman from buy to neutral, Goldman Sachs said. Valuation call, based on a $14 price target.

Louisiana-Pacific (LPX) downgraded at DA Davidson from neutral to underperform, DA Davidson said. $18 price target. Recent move is strand board prices is likely not sustainable.

Maxim (MXIM) downgraded at Credit Suisse from outperform to neutral, Credit Suisse said. $31 price target. Expect significant deterioration in the handset market.

Nucor (NUE) upgraded at Keybanc from hold to buy, Keybanc said. Company is leveraged to lagging commercial construction markets. $56 price target.

Old Dominion (ODEL) downgraded at Deutsche from buy to hold, Deutsche Bank said. Valuation call, based on a $40 price target.

Pharmacyclics (PCYC) downgraded at Lazard to neutral. Company lacks near-term catalysts.

Parexel (PRXL) upgraded at Goldman from sell to neutral, Goldman Sachs said. $36 price target. Company can continue to expand margins over the coming quarters.

Reliance Steel (RS) downgraded at Keybanc from buy to hold. Estimates also cut, given a lower pricing environment.

Sprint (S) downgraded at UBS to neutral from buy, UBS said. $6 price target. 2013 outlook/operational challenges should keep shares range bound in 1H.

Sprint downgraded at JP Morgan from overweight to neutral, JP Morgan said. $6 price target. Sales growth is decelerating.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AXP $78.93 0.00%
COF $79.87 0.00%
CSCO $27.25 0.00%
HPQ $31.29 0.00%
VZ $48.92 0.00%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs